Ordermade treatment using analysis of EGFR gene abnormality in non-small cell lung cancer

非小细胞肺癌EGFR基因异常分析的有序治疗

• 批准号: 17390385
• 负责人: FUJII Yoshitaka
• 金额: $ 9.28万
• 依托单位: NAGOYA CITY UNIVERSITY
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (B)
• 财政年份: 2005
• 资助国家: 日本
• 起止时间: 2005 至 2006
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-17390385/
• 关键词: lung cancer; gene; made-to-order

1. Using probes for the 13 different mutations including 11 that have already been reported, we have genotyped the EGFR mutation status in 400 non small cell lung cancer patients operated between 2000-2006 at Nagoya CityUniversity Hospital using the TaqMan PCR assay.We have evaluated the relationships among the EGFR mutation, clinical-pathologic factors, gefitinib sensitivity, and overall survival.We show in our previous paper that the TaqMan PCR assay is sensitive enough to detect the mutation in samples contaminated with 9 fold excess of wild type samples.Therefore, we have analyzed small samples obtained from CT guided biopsy or trans-bronchial biopsy.2. Some studies reported that downstream signaling molecules, EGFR gene amplification, and the expression of the other ErbB receptors were the other predictors of gefitinib sensitivity. Therefore, we have analyzed the other biomarkers, as the EGFR copy number, the ErbB2 copy number and PIK3CA gene mutation and have evaluated the relationship between their biomarkers and clinical-pathologic factors.3. We have reported these studies at the annual meetings and have published them as an article.4. In the future, we hope that EGFR mutation status using TaqMan PCR assay contributes to made-to-order treatment

1. Using probes for the 13 different mutations including 11 that have already been reported, we have genotyped the EGFR mutation status in 400 non small cell lung cancer patients operated between 2000-2006 at Nagoya CityUniversity Hospital using the TaqMan PCR assay.We have evaluated the relationships among the EGFR mutation, clinical-pathologic factors, gefitinib sensitivity, and overall survival.We show in our previous paper that the TaqMan PCR分析足够敏感，可以检测到被9倍过量的野生型样品污染的样品中的突变。因此，我们分析了从CT引导的活检或跨支气管检查的小样本。2。一些研究报告说，下游信号分子，EGFR基因扩增和其他ERBB受体的表达是吉非替尼灵敏度的其他预测指标。因此，我们已经分析了其他生物标志物，即EGFR拷贝数，ERBB2拷贝数和PIK3CA基因突变，并评估了其生物标志物与临床病理因素之间的关系。3。我们已经在年度会议上报告了这些研究，并将其出版为第4条。将来，我们希望使用TAQMAN PCR测定的EGFR突变状态有助于订购的治疗

项目成果

A Correlation Between EGFR Gene Mutation status and Brochioloalveolar Carcinoma Features in Japanese Patients with Adenocarcinoma

日本腺癌患者 EGFR 基因突变状态与细支气管肺泡癌特征的相关性

• 发表时间: 2006
• 期刊: Jpn J Clin Oncol 36(2)
• 作者: 峯田寿裕;田渕和雄;Hidefumi Sasaki;Hiroshi Haneda
• 通讯作者: Hiroshi Haneda

EGFR mutation status and prognosis for gefitinib treatment in Japanese lung cancer

• DOI: 10.1016/j.lungcan.2005.09.004
• 发表时间: 2006-01-01
• 期刊: LUNG CANCER
• 影响因子: 5.3
• 作者: Sasaki, H;Endo, K;Fujii, Y
• 通讯作者: Fujii, Y

L858R EGFR mutation status correlated with clinico-pathological features of Japanese lung cancer

• DOI: 10.1016/j.lungcan.2006.06.003
• 发表时间: 2006-10-01
• 期刊: LUNG CANCER
• 影响因子: 5.3
• 作者: Sasaki, Hidefumi;Endo, Katsuhiko;Fujii, Yoshitaka
• 通讯作者: Fujii, Yoshitaka

Epidermal growth factor receptor gene mutation defines distinct subsets among small adenocarcinomas of the lung

• DOI: 10.1016/j.lungcan.2005.12.005
• 发表时间: 2006-04-01
• 期刊: LUNG CANCER
• 影响因子: 5.3
• 作者: Haneda, H;Sasaki, H;Fujii, Y
• 通讯作者: Fujii, Y

EGFRvIII mutation in lung cancer correlates with increased EGFR copy number.

• DOI: 10.3892/or.17.2.319
• 发表时间: 2007-02
• 期刊: Oncology reports
• 影响因子: 4.2
• 作者: H. Sasaki;O. Kawano;K. Endo;H. Yukiue;M. Yano;Y. Fujii